Ig-HTS for disease progression or relapse in DLBCL in 2 patients. (A) A patient treated for limited stage DLBCL achieved a complete response and was shown on monitoring for plasma tumor DNA to have relapse before CT/PET detection of recurrent disease (lead time = 88 days). (B) A patient with 2 separate relapses detected by Ig-HTS coincident with radiologic relapse. Reprinted from Figure 5A-B in the article by Kurtz et al that begins on page 3679.